文献速递其他结缔组织病

循环胶原新表位在系统性硬化症纤维化预测中的作用:多中心队列研究

Circulating collagen neo-epitopes and their role in the prediction of fibrosis in patients with systemic sclerosis: a multicentre cohort study.
PubMed 文献 · Lancet Rheumatol · 2021-01-12

该多中心队列研究纳入符合2013年ACR/EULAR标准的系统性硬化症患者和健康对照,评估细胞外基质降解与形成新表位作为纤维化进展的血清生物标志物。主要结局为随访1年时纤维化进展。衍生队列显示III型和IV型胶原降解新表位及其转换率可区分进展者与非进展者,验证队列证实III型和IV型胶原新表位在进展者中改变。

要点

  • III型和IV型胶原降解新表位及其转换率可区分纤维化进展者与非进展者。
  • 验证队列证实III型和IV型胶原新表位在进展者中改变。
  • IV型胶原转换率和PRO-C3在多变量模型中显著预测皮肤进展。

核心结论

  • III型和IV型胶原新表位是评估和预测系统性硬化症细胞外基质重塑的有前景的生物标志物,可用于临床风险分层。

研究设计与样本

  • 多中心队列研究,包括衍生队列和验证队列,纳入符合2013年ACR/EULAR标准的系统性硬化症患者及健康对照。
  • 衍生队列纳入149例系统性硬化症患者(27例进展者,122例非进展者)和29例健康对照;验证队列纳入384例系统性硬化症患者(73例进展者)和60例健康对照。

主要发现

  • III型和IV型胶原新表位浓度在系统性硬化症患者中高于健康对照,并在单变量逻辑回归中与系统性硬化症显著相关。
  • 验证队列分析证实III型和IV型胶原新表位在进展者中改变。
  • 汇总分析中,皮肤进展者的PRO-C3、PRO-C4和IV型胶原转换率(PRO-C4:C4M)更高;IV型胶原转换率和PRO-C3在调整mRSS、性别和年龄的多变量模型中显著预测皮肤进展。

关键数值与推荐

  • 纤维化进展定义:间质性肺病患者用力肺活量占预计值百分比下降≥10%,或1年随访时改良Rodnan皮肤评分增加≥25%且>5分。
  • 使用经验证的ELISA测量细胞外基质降解新表位(BGM、C3M、C4M、C6M)和形成新表位(PRO-C1、PRO-C3、PRO-C4、PRO-C5、PRO-C6)。

临床怎么用

  • III型和IV型胶原新表位可用于临床风险分层,识别纤维化进展风险较高的系统性硬化症患者。

局限性

  • 原文未报告资助来源(None)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Extracellular matrix remodelling is a hallmark of systemic sclerosis. We evaluated extracellular matrix neo-epitopes as potential serum biomarkers for progression of fibrosis in systemic sclerosis. METHODS: We included patients meeting the 2013 American College of Rheumatology and European League Against Rheumatism criteria and healthy controls from a derivation and validation cohort. The primary outcome was progression of fibrosis at follow-up, defined as decline in percentage of predicted forced vital capacity of 10% or more in patients with interstitial lung disease or increase in modified Rodnan skin score of 25% or more and more than 5 points at a 1-year follow-up visit. Longitudinal assessment and biobanking followed European Scleroderma Trials and Research standards. Extracellular matrix-degradation (BGM, C3M, C4M, and C6M) and extracellular matrix-formation neo-epitopes (PRO-C1, PRO-C3, PRO-C4, PRO-C5, and PRO-C6) were measured in serum using validated ELISAs. FINDINGS: Between Aug 18, 2011, and Jan 19, 2015, 149 patients with systemic sclerosis (27 [18%] progressors and 122 [82%] non-progressors) and 29 healthy controls were included in the derivation cohort. Concentrations of type III and IV collagen neo-epitopes were higher in patients with systemic sclerosis compared with healthy controls and were significantly associated with systemic sclerosis in univariable logistic regression. Concentrations of degradation neo-epitopes of type III and IV collagens and their turnover ratios distinguished between progressors and non-progressors (C3M area under the curve 0·77 [95% CI 0·67-0·86], p<0·0001; PRO-C3:C3M 0·70 [0·59-0·80], p=0·0013; C4M 0·73 [0·63-0·82], p<0·0001; PRO-C4:C4M 0·75 [0·64-0·86], p<0·0001). 384 patients with systemic sclerosis (73 [19%] progressors) and 60 healthy controls were included in the multicentre validation cohort between April 17, 2003, and Jan 24, 2017. Analysis of the validation cohort confirmed that neo-epitopes of type III and IV collagens are changed in progressors. In a pooled analysis of both cohorts, the serum concentrations of formation neo-epitopes PRO-C3 and PRO-C4 and the turnover ratio of type IV collagen (PRO-C4:C4M) were higher in skin progressors. The turnover ratio of type IV collagen and PRO-C3 significantly predicted skin progression in a multivariable model adjusted for modified Rodnan skin score, sex, and age. INTERPRETATION: These data suggest that neo-epitopes of type III and IV collagens are promising biomarkers for the assessment and prediction of extracellular matrix remodelling in systemic sclerosis. They could be used in clinical practice to risk stratify patients at risk of progression of fibrosis. FUNDING: None.

来源:Lancet Rheumatol,查看原文。版权归原作者所有。

引用

  1. Dobrota R, Jordan S, Juhl P, et al. Circulating collagen neo-epitopes and their role in the prediction of fibrosis in patients with systemic sclerosis: a multicentre cohort study. Lancet Rheumatol. 2021. PMID: 38279380. doi:10.1016/S2665-9913(20)30385-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。